Other languages Kadimastem Ltd

Equities

KDST

IL0011284614

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 10:24:31 2024-05-30 am EDT			5-day change	1st Jan Change
501.2 ^ILa	+10.52%		+4.42%	-15.48%

Mar. 28	Kadimastem Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 28	IMC Announces Potential Reverse Merger With A Leading Clinical Cell Therapy Company	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IMC announces the termination of a preliminary term sheet with Kadimastem Ltd., a public company traded on the Tel Aviv Stock Exchange to fully focus on the recently legalized German market	May. 28
Kadimastem Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
IMC Announces Potential Reverse Merger With A Leading Clinical Cell Therapy Company	Feb. 28
Kadimastem Takes Another Step Towards Signing the Merger Agreement with Nasdaq Listed IMCC	Feb. 28
IMC Announces Potential Reverse Merger with Kadimastem a leading Clinical cell therapy company	Feb. 28
Kadimastem Ltd entered into a non-binding term sheet to acquire IM Cannabis Corp. in reverse merger transaction.	Feb. 27
Kadimastem Plans Listing on Nasdaq Through Merger	Feb. 18
Kadimastem advances towards Nasdaq: Company Signs a Memorandum of Understanding to Merge with a Company traded on the Nasdaq	Feb. 16
Kadimastem Receives Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in India	Feb. 07
A peer reviewed article on Kadimastem's AstroRxÃ‚® Cryopreserved off the Shelf Cell Product for the Treatment of ALS was Published in the Journal of Clinical Toxicology	Jan. 25
Kadimastem and iTolerance Complete Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting with the U.S. FDA	Jan. 22
ITolerance, Inc. and Kadimastem Ltd. Submit Initial Targeted Engagement for Regulatory Advice on CBER Products	Nov. 07
Kadimastem and iTolerance Submit Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting Request with FDA for Potential Cure for Type 1 Diabetes	Nov. 07
Kadimastem Ltd announced that it expects to receive ILS 6.783 million in funding from Alpha Capital Anstalt and another investor	23-10-15
Kadimastem Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31
Kadimastem Receives US Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes	23-06-20
Kadimastem : Granted a Patent in Israel for the Directed Differentiation of Astrocytes from Human Pluripotent Stem Cells (AstroRx®) for use in Drug Screening and the Treatment of ALS	21-03-09
Kadimastem : Announces Executive Management Changes	21-02-01
Kadimastem : AstroRx® shows promise in early phase amyotrophic lateral sclerosis trial	20-12-16
Kadimastem : Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in ALS	20-08-03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Kadimastem Ltd

Equities

KDST

IL0011284614

Other languages

Filters